We caught up with Dr. Joel M. Gelfand (Penn Medicine; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA) to discuss the findings from the phase IV study, investigating the impact of apremilast on vascular inflammation and cardiometabolic function when used in the treatment of psoriasis.
The abstract ‘A Phase IV, Open Label Study of the Effects of Apremilast on Vascular Inflammation and Cardiometabolic Function in Psoriasis’ was presented at AAD-VMX 2022, 25-29 March.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the AAD. Â
Questions
- What impact does psoriatic disease have on cardiovascular mortality? (0:14)
- How can cardiovascular mortality risk be determined clinically? (1:17)
- In two randomized trials, what effect did psoriatic disease treatments have on markers of cardiovascular inflammation? (3:36)
- In the open-label study you presented at AAD-VMX 2022, did apremilast continue to demonstrate treatment benefits and is any further research needed? (5:29)
Disclosures: Joel M. Gelfand discloses consulting for Abbvie, BMS, Boehringer Ingelheim, Celldex (DSMB), FIDE (which is sponsored by multiple pharmaceutical companies) GSK, Happify, Lilly (DMC), Leo, Janssen Biologics, Neumentum, Novartis Corp, Pfizer, UCB (DSMB), Neuroderm (DSMB), Regeneron, Trevi, and Mindera Dx; and grant/ research support from Amgen, Boehringer Ingelheim, and Pfizer Inc.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the AAD-VMX annual meeting 2022.
